Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Arcadia Biosciences (RKDA) Shares Outstanding (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Shares Outstanding readings, the most recent being $1.4 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 0.6% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 0.6% increase, with the full-year FY2025 number at $1.4 million, up 0.6% from a year prior.
  • Shares Outstanding hit $1.4 million in Q4 2025 for Arcadia Biosciences, roughly flat from $1.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $22.2 million in Q3 2021 to a low of $554609.0 in Q4 2021.
  • Median Shares Outstanding over the past 5 years was $1.4 million (2024), compared with a mean of $4.2 million.
  • Biggest five-year swings in Shares Outstanding: surged 146.55% in 2021 and later tumbled 97.5% in 2022.
  • Arcadia Biosciences' Shares Outstanding stood at $554609.0 in 2021, then grew by 11.08% to $616079.0 in 2022, then soared by 108.63% to $1.3 million in 2023, then increased by 6.19% to $1.4 million in 2024, then increased by 0.6% to $1.4 million in 2025.
  • The last three reported values for Shares Outstanding were $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.